Predictions
MacroGenics Inc.
Start price
Target price
Perf. (%)
€16.79
19.09.21
19.09.21
-
19.09.22
19.09.22
-79.51%
20.09.22
20.09.22
Probably not worthwhile Investment
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€25.05
19.09.21
19.09.21
-
19.09.22
19.09.22
-85.23%
20.09.22
20.09.22
Growths faster than the competition
Risky Investment
Celyad SA ADR
Start price
Target price
Perf. (%)
€3.58
19.09.21
19.09.21
-
19.09.22
19.09.22
-53.35%
20.09.22
20.09.22
Probably not worthwhile Investment
Riot Blockchain Inc.
Start price
Target price
Perf. (%)
€15.70
07.02.22
07.02.22
-
07.02.23
07.02.23
-60.50%
19.09.22
19.09.22
Could be worthwhile Investment >10% per year
Very high cyclical dependencies
Athersys Inc.
Start price
Target price
Perf. (%)
€2.21
15.09.22
15.09.22
€4.60
15.09.23
15.09.23
-15.60%
19.09.22
19.09.22
Could be very worthwhile Investment >20% year
Heat Biologics Inc.
Start price
Target price
Perf. (%)
€5.30
18.09.21
18.09.21
-
18.09.22
18.09.22
-63.56%
19.09.22
19.09.22
Risky Investment
High risks for its business
Dependend from few customers or products
Puma Biotechnology Inc.
Start price
Target price
Perf. (%)
€2.63
04.09.22
04.09.22
-
04.09.23
04.09.23
-6.99%
18.09.22
18.09.22
Could be worthwhile Investment >10% per year
Valneva SE
Start price
Target price
Perf. (%)
€11.82
14.09.21
14.09.21
€30.00
14.09.22
14.09.22
-29.36%
15.09.22
15.09.22
Could be worthwhile Investment >10% per year
Top 10 in its market
Future proof or reliable business model
Standard Investments for future growth
Assembly Biosciences Inc.
Start price
Target price
Perf. (%)
€2.76
12.09.21
12.09.21
€3.00
12.09.22
12.09.22
-24.82%
13.09.22
13.09.22
Could be worthwhile Investment >10% per year
Seres Therapeutics Inc
Start price
Target price
Perf. (%)
€4.99
12.09.21
12.09.21
€8.00
12.09.22
12.09.22
36.81%
13.09.22
13.09.22
Could be worthwhile Investment >10% per year
Inventiva SA
Start price
Target price
Perf. (%)
€11.54
10.09.21
10.09.21
€8.00
10.09.22
10.09.22
-63.65%
11.09.22
11.09.22
Could be worthwhile Investment >10% per year
Codexis Inc.
Start price
Target price
Perf. (%)
€34.80
05.11.21
05.11.21
€50.00
31.12.23
31.12.23
-79.99%
07.09.22
07.09.22
Could be very worthwhile Investment >20% year
Valneva SE
Start price
Target price
Perf. (%)
€24.64
16.12.21
16.12.21
€33.00
31.12.23
31.12.23
-67.02%
07.09.22
07.09.22
Could be very worthwhile Investment >20% year
Novavax Inc.
Start price
Target price
Perf. (%)
€202.35
31.08.21
31.08.21
€350.00
31.12.23
31.12.23
-85.81%
07.09.22
07.09.22
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€212.55
05.09.21
05.09.21
€333.00
05.09.22
05.09.22
-85.70%
06.09.22
06.09.22
Top 10 in its market
Could be worthwhile Investment >10% per year
Leading role in innovation
Very Future proof/growth oriented business model
MorphoSys AG
Start price
Target price
Perf. (%)
€30.80
08.01.22
08.01.22
-
08.01.26
08.01.26
-46.20%
05.09.22
05.09.22
Probably not worthwhile Investment
MorphoSys AG
Start price
Target price
Perf. (%)
€30.80
08.01.22
08.01.22
-
08.01.26
08.01.26
-46.20%
05.09.22
05.09.22
Probably not worthwhile Investment
Mirati Therapeutics Inc.
Start price
Target price
Perf. (%)
€76.50
21.08.22
21.08.22
€230.00
21.08.23
21.08.23
6.54%
04.09.22
04.09.22
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Probably not worthwhile Investment
Lower EBIT Margin than peer group
Mediwound Ltd.
Start price
Target price
Perf. (%)
€1.97
13.08.22
13.08.22
€5.00
13.08.23
13.08.23
-6.09%
04.09.22
04.09.22
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Mediwound Ltd.
Start price
Target price
Perf. (%)
€1.99
22.08.22
22.08.22
€4.00
22.08.23
22.08.23
-7.04%
04.09.22
04.09.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€214.90
21.08.22
21.08.22
€87.00
21.08.23
21.08.23
-3.44%
04.09.22
04.09.22
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group